Bristol-Myers Squibb Co.

NYSE:BMY   3:59:59 PM EDT
+1.03 (+1.30%)

Immatics, Bristol Myers Squibb Expand Alliance To Develop Gamma Delta Allogeneic Cell Therapy Programs

Published: 06/02/2022 11:20 GMT
Bristol-Myers Squibb Co. (BMY) - Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs.
Immatics - Immatics to Receive Upfront Payment of $60 Million and Additional Milestone Payments of Up to $700 Million per Program Plus Tiered Royalty Payments.
Immatics - Bristol Myers Squibb, Co Will Develop 2 Programs Owned by Bristol Myers, Both Cos Have Option to Develop Up to 4 Additional Programs Each.
Immatics - Co Will Be Responsible for Preclinical Development of Initial Two Bristol Myers Squibb-owned Programs.
Immatics - Co Will Receive Additional Payment for Certain Activities That Immatics Could Perform at Bristol Myers Squibb's Request.
Immatics - Bristol Myers Squibb and Immatics Will Expand Their 2019 Collaboration Agreement Focused on Autologous T Cell Receptor-based Therapy.
Immatics - As Part of Expansion, Immatics Will Receive an Upfront Payment of $20 Million and Be Eligible for Milestone Payments and Royalties.